Probiotic combination for treatment of inflammatory-related gastrointestinal disorders
AssigneeSociete des Produits Nestle S.A.
InventorsJalil BENYACOUB, Stéphane DUBOUX, Gail CZARNECKI-MAULDEN, Guénolée Eliane Marie PRIOULT, Gabriela BERGONZELLI DEGONDA
Life of this patent
Estimating the term…
Abstract
Disclosed is a probiotic combination comprising B. longum and B. lactis for the treatment or prevention of an inflammatory-related gastrointestinal disorder such as an inflammatory bowel disease.
Claims34
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.
(canceled)
(canceled)
A method for reducing gastrointestinal inflammation, reinforcing intestinal barrier, or for treating or preventing inflammatory bowel disease in a subject comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination is Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.
A method for prevention of inflammation-induced intestinal barrier dysfunction, reduction of intestinal barrier permeability, improvement of barrier repair, improvement of barrier function and/or reinforcement/protection of intestinal barrier in a subject, comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.
(canceled)
A method for reduction of gastrointestinal inflammation or for treatment or prevention of inflammatory-related gastrointestinal disorders in a subject, comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.
Dependencies are inferred from the claim text.